In May 2024, Bayer Pharmaceuticals Private Limited and Zydus Lifesciences Limited (formerly Cadila Healthcare) announced the conclusion of their joint venture, Bayer Zydus Pharma Private Limited.

Additionally, our acquisition of the remaining 25% stake in Bayer Zydus Pharma Private Limited strengthens our operations in India,” said Rai. “With full ownership, Bayer aims to align its ...

In a significant show of commitment to the African market, a high-powered delegation from the CFAO Group Headquarters in ...

Only 5-20% of India’s cultivable land undergoes soil testing. The centre addresses this gap with crop-specific, ...

GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable ...

Bayer stock trades 47% below our fair value estimate of $10.60 per share. We believe Bayer has created a narrow economic moat on the basis of the competitive advantages of the healthcare group.

Anti-Fungal Therapy Market. The global anti-fungal therapy market is set to experience significant growth, with a projected ...

Bayer CropScience ... board will consider raising funds by issuance of NCDs on private placement basis. Morepen Laboratories: The company incorporated a new subsidiary Morepen Medtech Ltd. NTPC Green: ...